CAS: 60643-86-9; Vigabatrin

该化合物是一种抗癫痫药物,主要用于治疗亚非复合性部分缉获和幼虫,被归类为伽马-氨丁酸(GABA)类似物和功能,不可逆转地抑制酶性GABA 转基因酶,导致大脑中甘巴沙丁酸浓度增加,从而增加抑制性...

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号7529-16-0 5-乙烯基-2-吡咯烷酮 | CAS号144085-15-4 4-benzenesulpho... | CAS号440366-57-4 4-(carbobenzylo... | CAS号54653-25-7 5-己烯酸乙酯 | CAS号31696-00-1 2-(丁-3-烯-1-基)丙二酸二乙酯 | CAS号440366-56-3 5-bromo-3-(carb... | CAS号440366-55-2 3-(carbobenzylo... | CAS号66855-20-7 (E)-6-hydroxy-h... | CAS号149815-86-1 ethyl 4-(2,2,2-... | CAS号105457-53-2 4-amino-5-fluor... | CAS号7529-16-0 5-乙烯基-2-吡咯烷酮

合成工艺路线路线简述

  • 合成目标产物 Vigabatrin 主要起始原料 5-Vinylpyrrolidone
  • (文献来源)合成步骤主要原料 5-Vinylpyrrolidone

海关参考信息

专利信息


专利号:US-9353057-B2
优先权日:2003-12-30
标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA
权利人:XENOPORT INC
摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

专利号:US-7576211-B2
优先权日:2004-09-30
标题 :Synthesis of thienopyridinone compounds and related intermediates
发明人:DHANOA DALE S; BECKER OREN; NOIMAN SILVIA; CHEN DONGLI; MARANTZ YAEL; SHACHAM SHARON; HEIFETZ ALEXANDER; INBAL BOAZ; BAR-HAIM SHAY; MOHANTY PRADYUMNA; LOBERA MERCEDES; WU LAURENCE
权利人:EPIX DELAWARE INC
摘要:The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

专利号:US-8017776-B2
优先权日:2003-07-15
标题 :Methods for synthesis of acyloxyalkyl compounds
发明人:BHAT LAXMINARAYAN; GALLOP MARK A
权利人:XENOPORT INC
摘要:Disclosed herein are methods for synthesizing 1-(acyloxy)-alkyl prodrug derivatives of drugs through oxidation of 1-acyl-alkyl derivatives of drugs under anhydrous reaction conditions. The methods typically proceed stereospecifically, in high yield, do not require the use of activated intermediates and/or toxic compounds and are readily amenable to scale-up.

专利号:US-2005080260-A1
优先权日:2003-04-22
标 题 :Preparation of prodrugs for selective drug delivery
发明人:MILLS RANDELL L; WU GUO-ZHANG
摘要:Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

专利号:US-2015158809-A9
优先权日:2013-02-26
标 题 :Method of making 1-(acyloxy)-alkyl carbamate compounds
发明人:WANG HUAN; LIU PENG; DAI QUNYING; YIN HAO; RAILLARD STEPHEN P
权利人:XENOPORT INC
摘要:Methods of preparing carbamate prodrugs of amine-containing drugs are provided. Carbonates useful in the synthesis of the carbamate prodrugs are also provided.

专利号:US-2008214827-A1
优先权日:2004-02-03
标 题:Synthesis of Cyanoimino-Benzoimidazoles
发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
权利人:EURO CELTIQUE SA
摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.
台州市科瑞生物技术有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.pharm-intermediates.com
企业联系电话:0576-88813233👤
📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
联系人:金崇光
电话:0576-88813233
手机:13396860566
传真:0576-88813233
邮箱:sales@pharm-intermediates.com
通信地址: 台州市开发大道东段288号
邮编: 318000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:台州市开发大道东段288号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Vigabatrin. 2022 Feb 20. 2012–. Vigabatrin. 2020 Jul 31. 27(2):197-204. doi: 10.1177/106002809302700215. 40 Suppl
5:S11-6. doi: 10.1111/j.1528-1157.1999.tb00914.x. 4(1):163-72. doi: 10.1016/j.nurt.2006.11.008.
6: Corrêa DG, Telles B, Freddi TAL. The vigabatrin-associated brain abnormalities on MRI and their differential diagnosis. Clin Radiol. 2024 Feb;79(2):94-101. doi: 10.1016/j.crad.2023.11.010. Epub 2023 Nov 29. 23(4):267-78. doi: 10.2165/00003088-199223040-00003. 38(4):442-450. doi: 10.1097/WNO.0000000000000609. 43(12):833-5. doi: 10.1017/s0012162201001517. 70(4):237-43. doi: 10.1111/j.1600-0773.1992.tb00465.x. (1):CD007302. doi: 10.1002/14651858.CD007302.pub2. Update in: Cochrane Database Syst Rev. 2020 Jul 30;7:CD007302. doi: 10.1002/14651858.CD007302.pub3. 300(6720):277-8. doi: 10.1136/bmj.300.6720.277.

合成参考文献


参考文献:10.1177/112067211002000419
摘要:Akçakaya AA, Gökçeer S, Erbil HH, Işik N, Özdöker L, Salar S, Aykan F, Aydin T, Yaylali SA, Kesim Ö. Detecting Retinal Vigabatrin Toxicity in Patients with Partial Symptomatic or Cryptogenic Epilepsy. European Journal of Ophthalmology. 2010 Jul;20(4):763–9. doi: 10.1177/112067211002000419.
参考文献:10.2165/11530220-000000000-00000
摘要:Michoulas A, Farrell K. Medical management of Lennox-Gastaut syndrome. CNS Drugs. 2010 May;24(5):363–74. doi: 10.2165/11530220-000000000-00000.
参考文献:10.4103/0971-6866.80353
摘要:Das A, Balan S, Banerjee M, Radhakrishnan K. Drug resistance in epilepsy and the ABCB1 gene: The clinical perspective. Indian J Hum Genet. 2011 May;17 Suppl 1():S12–21.
参考文献:10.1007/s13311-011-0058-9
摘要:De la Cruz E, Zhao M, Guo L, Ma H, Anderson SA, Schwartz TH. Interneuron Progenitors Attenuate the Power of Acute Focal Ictal Discharges. Neurotherapeutics. 2011 Jul 12;8(4):763–73. doi: 10.1007/s13311-011-0058-9.
参考文献:10.1002/glia.21202
摘要:Lee M, McGeer EG, McGeer PL. Mechanisms of GABA release from human astrocytes. Glia. 2011 Nov;59(11):1600–11. doi: 10.1002/glia.21202.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知